Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists

By sjmartinez • August 15, 2024

Rastogi A, Collins A, Kelepouris E, Kotzker W, Middleton JP, Rajpal M, Roy-Chaudhury P, Chertow GM. Practical Considerations and Implementation of Sodium-Glucose Co-Transporter-2 Inhibitors in Chronic Kidney Disease: Who, When, and How? A Position Statement by Nephrologists. J Prim Care Community Health. 2024 Jan-Dec;15:21501319241259905. doi: 10.1177/21501319241259905. PMID: 39143759.

Tags: Chronic kidney disease, consensus, KDIGO, Nephrology, Publications, SGLT2 inhibitor, treatment algorithm

Expanding Opportunities for Living Donation: Recommendations From the 2023 Santander Summit to Ensure Donor Protections, Informed Decision Making, and Equitable Access

Lentine KL, Waterman AD, Cooper M, Nagral S, Gardiner D, Spiro M, Rela M, Danovitch G, Watson CJE, Thomson D, Van Assche K, Torres M,[...]

Anti-Inflammatory Oxysterol, Oxy210, Inhibits Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells

Stappenbeck F, Wang F, Sinha SK, Hui ST, Farahi L, Mukhamedova N, Fleetwood A, Murphy AJ, Sviridov D, Lusis AJ, Parhami F. Anti-Inflammatory Oxysterol, Oxy210,[...]

Prevalence and Outcomes of Chronic Kidney Disease Associated Pruritus: International Results from PDOPPS

Tennankore KK, McCullough KP, Bieber B, Cho Y, Johnson DW, Kanjanabuch T, Kawanishi H, Kim YL, Lambie M, Rigatto C, Shen J, Schreiber M, Perl[...]